257 related articles for article (PubMed ID: 23418322)
1. Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity.
Kang TH; Mao CP; Lee SY; Chen A; Lee JH; Kim TW; Alvarez RD; Roden RB; Pardoll D; Hung CF; Wu TC
Cancer Res; 2013 Apr; 73(8):2493-504. PubMed ID: 23418322
[TBL] [Abstract][Full Text] [Related]
2. TLR9 acts as a sensor for tumor-released DNA to modulate anti-tumor immunity after chemotherapy.
Kang TH; Mao CP; Kim YS; Kim TW; Yang A; Lam B; Tseng SH; Farmer E; Park YM; Hung CF
J Immunother Cancer; 2019 Oct; 7(1):260. PubMed ID: 31619293
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral CpG-B Promotes Antitumoral Neutrophil, cDC, and T-cell Cooperation without Reprograming Tolerogenic pDC.
Humbert M; Guery L; Brighouse D; Lemeille S; Hugues S
Cancer Res; 2018 Jun; 78(12):3280-3292. PubMed ID: 29588348
[TBL] [Abstract][Full Text] [Related]
4. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
5. Dendritic Cells and Cancer Immunity.
Gardner A; Ruffell B
Trends Immunol; 2016 Dec; 37(12):855-865. PubMed ID: 27793569
[TBL] [Abstract][Full Text] [Related]
6. Polyarginine-mediated protein delivery to dendritic cells presents antigen more efficiently onto MHC class I and class II and elicits superior antitumor immunity.
Mitsui H; Inozume T; Kitamura R; Shibagaki N; Shimada S
J Invest Dermatol; 2006 Aug; 126(8):1804-12. PubMed ID: 16645583
[TBL] [Abstract][Full Text] [Related]
7. STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models.
Jing W; McAllister D; Vonderhaar EP; Palen K; Riese MJ; Gershan J; Johnson BD; Dwinell MB
J Immunother Cancer; 2019 Apr; 7(1):115. PubMed ID: 31036082
[TBL] [Abstract][Full Text] [Related]
8. Porous silicon microparticle potentiates anti-tumor immunity by enhancing cross-presentation and inducing type I interferon response.
Xia X; Mai J; Xu R; Perez JET; Guevara ML; Shen Q; Mu C; Tung HY; Corry DB; Evans SE; Liu X; Ferrari M; Zhang Z; Li XC; Wang RF; Shen H
Cell Rep; 2015 May; 11(6):957-966. PubMed ID: 25937283
[TBL] [Abstract][Full Text] [Related]
9. Anti-oxidative Amino Acid L-ergothioneine Modulates the Tumor Microenvironment to Facilitate Adjuvant Vaccine Immunotherapy.
Yoshida S; Shime H; Matsumoto M; Kasahara M; Seya T
Front Immunol; 2019; 10():671. PubMed ID: 31019508
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral administration of TLR4 agonist absorbed into a cellular vector improves antitumor responses.
Davis MB; Vasquez-Dunddel D; Fu J; Albesiano E; Pardoll D; Kim YJ
Clin Cancer Res; 2011 Jun; 17(12):3984-92. PubMed ID: 21543518
[TBL] [Abstract][Full Text] [Related]
11. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
[TBL] [Abstract][Full Text] [Related]
12. Physiological role of plasmacytoid dendritic cells and their potential use in cancer immunity.
Schettini J; Mukherjee P
Clin Dev Immunol; 2008; 2008():106321. PubMed ID: 19190769
[TBL] [Abstract][Full Text] [Related]
13. Drug Delivery for Cancer Immunotherapy and Vaccines.
Batty CJ; Tiet P; Bachelder EM; Ainslie KM
Pharm Nanotechnol; 2018; 6(4):232-244. PubMed ID: 30227827
[TBL] [Abstract][Full Text] [Related]
14. Immune Cell-Derived Exosomes in the Cancer-Immunity Cycle.
Yan W; Jiang S
Trends Cancer; 2020 Jun; 6(6):506-517. PubMed ID: 32460004
[TBL] [Abstract][Full Text] [Related]
15. Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME).
Bretz AC; Parnitzke U; Kronthaler K; Dreker T; Bartz R; Hermann F; Ammendola A; Wulff T; Hamm S
J Immunother Cancer; 2019 Nov; 7(1):294. PubMed ID: 31703604
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
da Cunha A; Antoniazi Michelin M; Cândido Murta EF
Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
[TBL] [Abstract][Full Text] [Related]
17. Incorporation of the Tat cell-penetrating peptide into nanofibers improves the respective antitumor immune response.
Mohammadi M; Dehghani P; Mohseninia A; Roozbehani M; Hemphill A; Hesamizadeh K
J Cell Physiol; 2021 Feb; 236(2):1401-1417. PubMed ID: 32686113
[TBL] [Abstract][Full Text] [Related]
18. Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication.
Zom GG; Willems MMJHP; Khan S; van der Sluis TC; Kleinovink JW; Camps MGM; van der Marel GA; Filippov DV; Melief CJM; Ossendorp F
J Immunother Cancer; 2018 Dec; 6(1):146. PubMed ID: 30541631
[TBL] [Abstract][Full Text] [Related]
19. Cancer immunotherapy employing an innovative strategy to enhance CD4+ T cell help in the tumor microenvironment.
Song L; Yang MC; Knoff J; Wu TC; Hung CF
PLoS One; 2014; 9(12):e115711. PubMed ID: 25531529
[TBL] [Abstract][Full Text] [Related]
20. Regulation of tumor immunity by tumor/dendritic cell fusions.
Koido S; Homma S; Hara E; Namiki Y; Takahara A; Komita H; Nagasaki E; Ito M; Ohkusa T; Gong J; Tajiri H
Clin Dev Immunol; 2010; 2010():516768. PubMed ID: 21048993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
